{"id":"afamelanotide-and-nb-uvb-light","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Darkening of skin and moles"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL4297213","moleculeType":"Protein","molecularWeight":"1706.93"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Afamelanotide is a synthetic analog of α-MSH that binds to melanocortin-1 receptors on melanocytes, triggering increased melanin synthesis and distribution. When combined with narrowband UVB (NB-UVB) phototherapy, the treatment synergistically enhances melanogenesis and provides photoprotective effects. This combination approach aims to restore protective pigmentation in patients with photosensitive disorders, reducing UV-induced damage and clinical symptoms.","oneSentence":"Afamelanotide stimulates melanin production via alpha-melanocyte-stimulating hormone (α-MSH) receptor activation, which is then enhanced by controlled NB-UVB light exposure to increase skin pigmentation and photoprotection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:00:04.248Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Erythropoietic protoporphyria (EPP)"},{"name":"X-linked protoporphyria (XLP)"}]},"trialDetails":[{"nctId":"NCT06109649","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo","status":"ACTIVE_NOT_RECRUITING","sponsor":"Clinuvel, Inc.","startDate":"2023-10-11","conditions":"Vitiligo","enrollment":200},{"nctId":"NCT04525157","phase":"PHASE2","title":"Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV)","status":"COMPLETED","sponsor":"Clinuvel Pharmaceuticals Limited","startDate":"2014-06-06","conditions":"Vitiligo","enrollment":21},{"nctId":"NCT01382589","phase":"PHASE2","title":"Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo","status":"COMPLETED","sponsor":"Clinuvel Pharmaceuticals Limited","startDate":"2011-09","conditions":"Vitiligo","enrollment":15},{"nctId":"NCT01430195","phase":"PHASE1","title":"Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV)","status":"COMPLETED","sponsor":"Clinuvel Pharmaceuticals Limited","startDate":"2011-06","conditions":"Vitiligo","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Afamelanotide and NB-UVB Light","genericName":"Afamelanotide and NB-UVB Light","companyName":"Clinuvel, Inc.","companyId":"clinuvel-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Afamelanotide stimulates melanin production via alpha-melanocyte-stimulating hormone (α-MSH) receptor activation, which is then enhanced by controlled NB-UVB light exposure to increase skin pigmentation and photoprotection. Used for Erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}